Point72 (Difc) LTD Erasca, Inc. Transaction History

Point72 (Difc) LTD

$2.44 Trillion
Q1 2025

A detailed history of Point72 (Difc) LTD transactions in Erasca, Inc. stock. As of the latest transaction made, Point72 (Difc) LTD holds 5,216 shares of ERAS stock, worth $8,189. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,216

Holding current value

$8,189

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 15, 2025	BUY	$1.28 - $2.75 $6,676 - $14,344	5,216 New	5,216 $7.15 Million
Q1 2024 May 15, 2024	BUY	$1.67 - $2.55 $12,391 - $18,921	7,420 New	7,420 $15.3 Million

Others Institutions Holding ERAS

# of Institutions

162

Shares Held

222M

Call Options Held

20.6K

Put Options Held

5.7K

Frazier Life Sciences Management, L.P. Menlo Park, CA

22.6M
Shares

$35.4 Million
1.95% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

17.3M
Shares

$27.1 Million
0.02% of portfolio
Vr Adviser, LLC New York, NY

16.2M
Shares

$25.5 Million
5.36% of portfolio
Logos Global Management LP San Francisco, CA

13M
Shares

$20.4 Million
3.47% of portfolio
Vanguard Group Inc Valley Forge, PA

12.7M
Shares

$20 Million
0.0% of portfolio

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $192M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 (Difc) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 (Difc) LTD with notifications on news.

Account